Sign In
Buy FLGT
$18.14
-0.560 (-2.99%)
At Close: Jun 03, 2026
Fulgent Presents Updated FID-007 Data at ASCO 2026
07:00pm, Monday, 01'st Jun 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with established laboratory services and therapeutic developme
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Fulgent Genetics, Inc. (“Fulgent” or the
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a the
SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Fulgent Genetics, Inc. (NASDAQ: FLGT). The investigation focuses on Fulgent
NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Fulgent Genetics, Inc. (“Fulgent” or the
Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics
07:00am, Monday, 04'th May 2026
BOSTON & EL MONTE, Calif.--(BUSINESS WIRE)--FoundationOne®PGx helps guide cancer therapy selection and dosing strategies to support safer, more effective patient care.
Fulgent Genetics, Inc. (FLGT) Q1 2026 Earnings Call Transcript
12:21pm, Friday, 01'st May 2026
Fulgent Genetics, Inc. (FLGT) Q1 2026 Earnings Call Transcript
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Beats Revenue Estimates
09:10am, Friday, 01'st May 2026
Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to earnings of $0.04 per share a year ago.
Fulgent Reports First Quarter 2026 Financial Results
07:00am, Friday, 01'st May 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a th
Fulgent Genetics, Inc. (NASDAQ:FLGT) Given Average Rating of “Hold” by Analysts
04:24am, Thursday, 23'rd Apr 2026
Shares of Fulgent Genetics, Inc. (NASDAQ: FLGT - Get Free Report) have been assigned an average recommendation of "Hold" from the five analysts that are covering the company, MarketBeat reports. One a
Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting
04:05pm, Wednesday, 22'nd Apr 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a the
NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Fulgent Genetics, Inc. (“Fulgent” or th
Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026
07:30am, Thursday, 16'th Apr 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a the
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Fulgent (FLGT) To Contact Him Directly To Discuss Their Options
Fulgent Genetics, Inc. (NASDAQ:FLGT) Sees Large Increase in Short Interest
03:13am, Tuesday, 31'st Mar 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT - Get Free Report) was the recipient of a large growth in short interest in the month of March. As of March 13th, there was short interest totaling 2,135,898 share
